assignment i solubility
TRANSCRIPT
-
8/22/2019 Assignment I Solubility
1/24
The assignment on
Various Approaches for Enhancing Solubility of Drug Molecules
Assignment no: 1
Drug Delivery system I
M.Pharm, (2012-2014)
Industrial Pharmacy
First semester
Submitted to:
Prof. Dr. Panna Thapa,
Head of Department, Pharmacy Department,
Dean, School of Science
Kathmandu University
Dhulikhel, Kavre.
Submitted by:
Achyut Bikram Thapa
-
8/22/2019 Assignment I Solubility
2/24
Table of Content
1. Solution and solubility ............................................................................................. 32. Methods of expressing solubility ............................................................................. 33. Biopharmaceutics classification system of drugs .................................................... 54. Types of solution...................................................................................................... 55. General consideration for solubility determination of solids in liquids ................... 66. Determination of solubility of solids in liquid ......................................................... 77. Process of solubalization of drugs ........................................................................... 88. Rate of solution ........................................................................................................ 99. Factors affecting the solubility of solids in liquids ................................................ 1010. Methods of enhancing the solubility ...................................................................... 1311. Conclusion ............................................................................................................. 2112. References .............................................................................................................. 22
List of Tables
Table 1: Descriptive terms for solubility ............................................................................ 4Table 2: Types of solution .................................................................................................. 5
List of Figures
Figure 1: Process of solubalization of solute in solvent ..................................................... 8Figure 2: Process of absorption of drug from various dosage forms. ................................. 9Figure 3: Solubility enhancement approaches for poorly soluble drug. ........................... 14
-
8/22/2019 Assignment I Solubility
3/24
Various Approaches for Enhancing Solubility of Drug Molecules
1. Solution and solubilityA solutioncan be defined as a system in which molecules of a solute (such as a drug or
protein) are dissolved in a solvent vehicle. When a solution contains a solute at the limit
of its solubility at any given temperature and pressure, it is said to besaturated. If the
solubility limit is exceeded, solid particles of solute may be present and the solution
phase will be in equilibrium with the solid, although under certain circumstances
supersaturated solutions may be prepared, where the drug exists in solution above its
normal solubility limit [1].
The solubility of a substance in a solvent at a given temperature and pressure, is the
amount of substance that has passed into solution when equilibrium is attained between
the solution and excess, i.e. undissolved substance. The solution that is obtained under
these conditions is termed as saturated solution. It is possible to obtain solutions that are
supersaturated. However, they are unstable and scratching the side of the container, the
presence of dust, or the addition of undissolved solute will provide nuclei that readily
lead to precipitation of the excess solute [2].
2. Methods of expressing solubilityWhen quantitative data are available, solubilities are expressed in many ways. The British
Pharmacopoeia expresses solubilities as the number of parts by volume of solvent
required to dissolve one part by weight of a solid or one part by volume of a liquid.
Unless otherwise specified, these solubilities apply at room temperature [2].
When special quantitative solubility tests are given in the compendia, these solubilities
can be used as a criterion for assessing the purity of the compound. Whenever the exact
solubility of a pharmaceutically important compound is not know or designated, the
following descriptive terms (U.S.P. XVIII and N.F. XIII) can be used [3]:
-
8/22/2019 Assignment I Solubility
4/24
Table 1: Descriptive terms for solubility
Descriptive term Parts of solvent for 1 part of solute
Very soluble Less than 1
Freely soluble From 1 to 10
Soluble From 10 to 30
Sparingly soluble From 30 to 100
Slightly soluble From 100 to 1000
Very slightly soluble From 1000 to 10,000
Practically insoluble or insoluble More than 10,000
The WHO defines the term high solubility for expression of solubility factor.An API is considered highly soluble when the highest dose recommended by WHO (if
the API appears on the WHO Model List of Essential Medicines) or highest dose strength
available on the market as a oral solid dosage form (if the API does not appear on the
WHO Model List of Essential Medicines) is soluble in 250 ml or less of aqueous media
over the pH range of 1.26.8. The pH-solubility profile of the API should be determined
at 37 1 C in aqueous media. A minimum of three replicate determinations of solubility
at each pH condition is recommended. Initial recommendations in the BCS Guidance
suggested that the solubility should be measured over a pH range of 1.27.5. But
successive scientific discussions and publications suggest that a pH range of 1.26.8 is
more appropriate [4].
The reason for the 250-ml cut-off criterion for the dose: solubility ratio is that in
pharmacokinetic bioequivalence studies, the API formulation is to be ingested with a
large glass of water (8 ounces corresponds to about 250 ml). If the highest orally
administered dose can be completely dissolved in this amount of water, independent of
the physiological pH value (hence the determination over the pH range 17.5), solubility
problems are not expected to hinder the uptake of the API in the small intestine [5].
-
8/22/2019 Assignment I Solubility
5/24
3. Biopharmaceutics classification system of drugsThe Biopharmaceutics Classification System (BCS) is based on aqueous solubility and
intestinal permeability of the drug substance. It classifies the API into one of four classes
[4]:
Class 1: high solubility, high permeability
Class 2: low solubility, high permeability
Class 3: high solubility, low permeability
Class 4: low solubility, low permeability
As per the data collected, the drugs under class II and IV are requiring special attention
during formulation of oral solid dosage form, or in liquid dosage form. Only about 8% of
newer drugs fall under class I [6].
4. Types of solutionSolutions may be classified based on the physical state of the components. Since there are
three states of matter, i.e. solid, liquid and gas, nine different types of solution with two
components are possible [2].
Table 2: Types of solution
solute SolventGas Gas
Liquid Gas
Solid Gas
Gas Liquid
Liquid Liquid
Solid Liquid
Gas SolidLiquid Solid
Solid Solid
-
8/22/2019 Assignment I Solubility
6/24
5. General consideration for solubility determination of solids in liquidsIt is necessary to know the solubilities when preparing and dispensing medicines.
Information of solubility is also necessary for separation of substances in quantitative and
qualitative analysis [7].
The details of the determination of the solubility are affected markedly by the physical
and chemical characteristics of the solute and solvent and by the temperature at which the
solubility is determined. Accordingly, it is not possible to describe a universally
applicable method, but in general, the following rules must be observed in solubility
determinations [7].
a. The solvent and solute must be pure.b. A saturated solution must be obtained before any solution is removed for
analysis.
c. The method of separating a sample of saturated solution from undissolved solutemust be satisfactory.
d. The method of analyzing the solution must be reliable.e. Temperature must be adequately controlled.
A saturated solution is obtained either by stirring excess of powdered solute with solvent
for several hours at the required temperature until equilibrium has been attained, or by
warming the solvent with an excess of the solute and allowing the mixture to cool to the
required temperature. It is essential that some undissolved solid should be present at the
completion of this stage in order to ensure that the solution is saturated [2].
A sample of the saturated solution is obtained for analysis by separating the solution from
the undissolved solid. Filtration is usually used, but precautions should be taken to ensure
that:
a.It is carried out at the temperature of the solubility determination, in order toprevent any change in the equilibrium between dissolved and undissolved solute.
b.Loss of a volatile component does not occur.
-
8/22/2019 Assignment I Solubility
7/24
6. Determination of solubility of solids in liquidDifferent method of analysis may be applied to the saturated solution depending on the
type of system involved.
a. Shake flask method:According to Health and Human Services, Food and Drug Administration (HHS-FDA )
guidance, the determination of the equilibrium solubility should be carried out with the
shake flask method (other methods such as acid or base titration are permitted when their
ability to predict the equilibrium solubility is justified). The experiments should be
carried out at a temperature of 371C. Further, a sufficient number of pH conditions
should be chosen to cover the pH range of 17.5 and each determination should be
carried out at least in triplicate. The buffer solutions given in the United States
Pharmacopeia (USP) are appropriate for the tests, but other buffers are alsoallowed for
these experiments. The pH value of each buffer solution should bechecked before and
after each experiment. Degradation of the API due to pHor buffer composition should be
reported together with other stability data [5].
b. Heating:If one of the components is volatile and one is non-volatile, the amount of latter can be
determined by heating to constant weight [2].
c. Conversion of solute:The solute is to an insoluble compound by chemical reaction and weight of this insoluble
compound may be obtained after filtration and drying [2].
d. Volumetric analysis:This method is used especially for the compounds that exhibit the reactions with acids,
alkalis, chlorides, etc. that readily determines the solubility [2].
e. Physical method:Physical measurements offer a further means of analysis. A measurement of electrical
conductivity is suitable for sparingly soluble electrolytes, optical rotation may be used for
optically active compounds, or a radioactive indicator method of analysis may be
employed. For radioactive method, the test material is prepared in such a way that it
-
8/22/2019 Assignment I Solubility
8/24
contains a know proportion of a radioactive indicator. A saturated solution is made and
its level of radioactivity may be used to determine the concentration of solute [2].
7. Process of solubalization of drugsThe process of solubilisation involves the breaking of inter-ionic or intermolecular bonds
in the solute, the separation of the molecules of the solvent to provide space in the solvent
for the solute, interaction between the solvent and the solute molecule or ion [8].
Step 1: Holes opens in the solvent
Step2: Molecules of the solid breaks away from the bulk
Step 3: The freed solid molecule is integrated into the hole in the solv
Figure 1: Process of solubalization of solute in solvent
The drugs are designed in different dosage form e.g. solid, liquid, semi solid,
transdermal. API in class 1 and 3 of BCS are readily soluble and thus are of lessimportance in solubility considerations. Drugs in class 2 and 4 of BCS need special
attention during formulation.
Oral drug dosage forms undergo following pathway of solubalization before it reaches to
blood circulation and finally to the site of action. Solid dosage forms of tablets and
capsules undergo process of disintegration to result granules. These granules and coarse
-
8/22/2019 Assignment I Solubility
9/24
powder is changed to fine particles by disaggregation of granular particles. Fine particles
undergo process of dissolution and the drug particles gets to solution and eventually to
blood after absorption.
Disintegration
Dissolution of shell Disaggregation
Absorption from biological
membrane
Figure 2: Process of absorption of drug from various dosage forms.
8. Rate of solutionThe measurement of speed by which the solute turns into solution is known as rate of
solution [9].
There are different factors affecting the rate of solution, i.e.
a. Size of the particles
Tablets
Capsules
Powder
Coarse
Suspension
Granules
Drug in solution
Solution
Fine particles
Emulsion
Dissolution
Drug in blood
Rateofabsor
ption
-
8/22/2019 Assignment I Solubility
10/24
When the total surface area of the solute particles is increased, the solute dissolves more
rapidly because the action takes place only at the surface of each particle. Breaking a
solute into smaller pieces increases its surface area and hence its rate of solution.
b. TemperatureFor liquids and solid solutes, increasing the temperature not only increases the amount of
solute that will dissolve but also increases the rate at which the solute will dissolve. For
the gases, reverse is true.
c. Amount of solute already dissolvedWhen there is little solute already in solution, dissolution takes place relatively rapidly.
As the solution approaches the point where no solute can be dissolved, dissolution takes
place more slowly.d. Stirring
With liquid and solid solutes, stirring brings fresh portions of the solvent in contact with
the solute, thereby increasing the rate of solution.
Different estimates shows about 50% of the new molecules developed with
pharmacological importance are dropped due to poor solubility or insolubility. As the
molecules are not soluble, they cannot make them bioavailable in sufficient quantity so
could not produce desired level of pharmacological responses. In solid mainly following
two factors causes the poor solubility in water [10]
a. Strong intermolecular interactions that makes the solubilization expensiveb. High lipophilicity9. Factors affecting the solubility of solids in liquids
The solubility depends on the physical form of the solid, the nature and composition of
solvent medium as well as temperature and pressure of system [9].a. Particle Size
The size of the solid particle influences the solubility because as a particle becomes
smaller, the surface area to volume ratio increases. The larger surface area allows a
greater interaction with the solvent. The effect of particle size on solubility can be
described by following equation
http://www.pharmainfo.net/tablet-evaluation-tests/dissolutionhttp://www.pharmainfo.net/tablet-evaluation-tests/dissolutionhttp://www.pharmainfo.net/tablet-evaluation-tests/dissolutionhttp://www.pharmainfo.net/tablet-evaluation-tests/dissolution -
8/22/2019 Assignment I Solubility
11/24
Where,
S is the solubility of infinitely large particles
S0 is the solubility of fine particles
V is molar volume
g is the surface tension of the solid
r is the radius of the fine particle
b. TemperatureTemperature will affect solubility. If the solution process absorbs energy then the
solubility will be increased as the temperature is increased. If the solution process
releases energy then the solubility will decrease with increasing temperature7. Generally,
an increase in the temperature of the solution increases the solubility of a solid solute. A
few solid solutes are less soluble in warm solutions. For all gases, solubility decreases as
the temperature of the solution increases [9].
c. PressureFor gaseous solutes, an increase in pressure increases solubility and a decrease in
pressure decreases the solubility. For solids and liquid solutes, changes in pressure have
practically no effect on solubility [9].
d. Nature of the solute and solventWhile only 1 gram of lead (II) chloride can be dissolved in 100 grams of water at room
temperature, 200 grams of zinc chloride can be dissolved. The great difference in thesolubility of these two substances is the result of differences in their natures [9].
e. Molecular sizeMolecular size will affect the solubility. The larger the molecule or the higher its
molecular weight the less soluble the substance. Larger molecules are more difficult to
-
8/22/2019 Assignment I Solubility
12/24
surround with solvent molecules in order to solvate the substance. In the case of organic
compounds the amount of carbon branching will increase the solubility since more
branching will reduce the size (or volume) of the molecule and make it easier to solvate
the molecules with solvent [11].
f. PolarityPolarity of the solute and solvent molecules will affect the solubility. Generally non-polar
solute molecules will dissolve in non-polar solvents and polar solute molecules will
dissolve in polar solvents. The polar solute molecules have a positive and a negative end
to the molecule. If the solvent molecule is also polar, then positive ends of solvent
molecules will attract negative ends of solute molecules. This is a type of intermolecularforce known as dipole-dipole interaction. All molecules also have a type of
intermolecular force much weaker than the other forces called London Dispersion forces
where the positive nuclei of the atoms of the solute molecule will attract the negative
electrons of the atoms of a solvent molecule. This gives the non-polar solvent a chance to
solvate the solute molecules [11].
g. PolymorphsA solid has a rigid form and a definite shape. The shape or habit of a crystal of a given
substance may vary but the angles between the faces are always constant. A crystal is
made up of atoms, ions, or molecules in a regular geometric arrangement or lattice
constantly repeated in three dimensions. This repeating pattern is known as the unit cell.
The capacity for a substance to crystallize in more than one crystalline form is
polymorphism. It is possible that all crystals can crystallize in different forms or
polymorphs. If the change from one polymorph to another is reversible, the process is
called enantiotropic. If the system is monotropic, there is a transition point above the
melting points of both polymorphs. The two polymorphs cannot be converted from one
another without undergoing a phase transition. Polymorphs can vary in melting point.
Since the melting point of the solid is related to solubility, so polymorphs will have
-
8/22/2019 Assignment I Solubility
13/24
different solubilities3. Generally, the range of solubility differences between different
polymorphs is only 2-3 folds due to relatively small differences in free energy [12].
10.Methods of enhancing the solubilityTo overcome the factors influencing the solubility, as discussed above, there are different
techniques which are in practice are as follows [13]
I. Physical Modificationa. Particle size reduction
i. Micronizationii. Nanosuspension
iii. Sonocrystallizationiv. Super critical fluid processv. Spray drying
b. Modification of the crystal habiti. Polymorphs
ii. Pseudopolymorphsc. Drug dispersion in carriers
i.
Eutectic mixturesii. Solid dispersions
iii. Solid solutiond. Complexation
i. Stacking complexii. Inclusion complex
e. Solubilization by surfactantsi. Microemulsion
ii. Self microemulsifying drug delivery systemII. Chemical modification
a. Change in pHb. Changing in salt form
III. Other techniques
-
8/22/2019 Assignment I Solubility
14/24
a. Co-crystallizationb. Co-solvencyc. Hydrotrophyd. Solubilizing agentse. Nanotechnologies
The techniques to enhance the solubility are in practice from long ago and they have
greatly contributed for improving the solubility of poorly soluble drug materials.
Techniques like sonocrystallization, nanosuspension, solid dispersion; super critical fluid
process, microemulsion, self-emulsifying drug delivery system etc are novel techniques.
These techniques are under studies in recent years.
From the side of formulation approaches, the solubility enhancement of poorly soluble
drug can be represented as follows [14]
Figure 3: Solubility enhancement approaches for poorly soluble drug.
Among the different techniques of improving the solubility of drug substances, some of
the techniques appreciated and kept in further research are discussed in following
paragraphs.
a. Self emulsifying drug delivery system
-
8/22/2019 Assignment I Solubility
15/24
It is the drug delivery system designed with the use of surfactants of HLB value lesser
than 12. In this system the drug molecules are mixed with oils like corn oil, soya bean oil,
hydrogenated vegetable oil etc, surfactants like tween 80, sodium dodecyl benzene
sulphonate etc, co-surfactants likepolyoxyehtylated glycerides, D-alpha Tocopheryl
polyethylene glycol 1000 succinate etc and cosolvents like ethanol, glycerine,
polyethylene glycol etc, consistency builders like beeswax, tragacanth etc, polymers like
ethyl cellulose, hydroxyl propyl methyl cellulose etc, and the preparations designed in
soft gelatin capsules or in hard gelatin capsules [15].
There are certain advantages of this system-
i. After reaching to gastric fluid and due to movement of gastrointestinal tract,the system get dissolve in gastric fluid, it forms oil in water emulsions,promoting the wide distribution and minimize the irritation, the formed
emulsion is said as micro emulsion thus the system is somewhere called as
self micro emulsifying drug delivery system.
ii. Provides large interfacial surface area for partitioning of drug between oil andwater.
iii. Give physically stable formulation so easy to manufacture.
b. Solid dispersion techniquesChiou and Riegelman defined solid dispersion as the dispersion of one or more active
ingredients in as inert excipient or matrix, where the active ingredients could exist in
finely crystalline, solubilized or amorphous stage. The most commonly used hydrophilic
base is polyvinylpyrrolidine K 30, polyethylene glycols, Plasdone-S630. Many times
surfactants may also used in the formation of solid dispersion. Surfactants like Tween-80,
Docusate sodium, Myrj-52, Pluronic-F68 and Sodium Lauryl Sulphate used [15].
c. Super critical fluid processSuper critical fluid process is a novel nano sizing and solubilization technology whose
application has increased particle size reduction using a supercritical fluid (SCF) [16].
-
8/22/2019 Assignment I Solubility
16/24
A supercritical fluid (SCF) is a dense non-condensable fluid whose temperature and
pressure are greater than its critical temperature (Tc) and critical pressure (Tp). Through
manipulation of the pressure of SCFs, the favorable characteristics of gases- high
diffusivity, low viscosity and low surface tension may be imparted upon liquids to
precisely control the solubilisation of a drug with a SCF [17].
SCFs are high compressible, allowing moderate changes in pressure to greatly alter the
density and mass transport characteristics of fluid that largely determine its solvents
power. Once the drug particles are solubilised within SCFs, they may be re-crystallized at
greatly reduced particle sizes. A SCF process allows micronisation of drug particles
within narrow range of particle size, often to sub-micron levels. Current SCF processes
have demonstrated the ability to create nano particulate suspensions of particles 5 to2,000 nm in diameter.
The most widely employed methods of SCF processing for micronized particles are rapid
expansion of supercritical solutions (RESS) and gas anti solvents recrystallisation (GAS),
both of which are employed by the pharmaceutical industry using carbon dioxide (CO2)
as the SCF [16].
CO2 is used as SCF due to its favourable processing characteristics like its low critical
temperature (Tc = 31.1-C) and pressure (Pc = 73.8 bar) [18].
RESS involves solubilising a drug or a drug-polymer mixture in SCF and subsequently
spraying the SCF solution into a lower pressure environment via a conventional nozzle or
capillary tube. The rapid expansion undergone by the solution reduces the density of the
CO2, correspondingly reducing its solvent power and supersaturating the lower pressure
solution. This supersaturation results in the recrystallisation and precipitation of pure
drug or drug-polymer particles of greatly reduced size, narrow size distribution and high
purity. The solubility of nifedipine has been improved by RESS [19].
GAS processing requires the drug or drug-polymer mixture be solubilised via
conventional means into a solvent that is then sprayed into an SCF; the drug should be
insoluble in the SCF, while the SCF should be miscible with the organic solvent. The
SCF diffuses into the spray droplets, causing expansion of the solvent present and
precipitation of the drug particles.
-
8/22/2019 Assignment I Solubility
17/24
The low solubility of poorly water-soluble drugs and surfactants in supercritical CO2 and
the high pressure required for these processes restrict the utility of this technology in the
pharmaceutical industry [20].
d. Inclusion ComplexesInclusion complexes are formed by the insertion of the nonpolar molecule or the nonpolar
region of one molecule (known as guest) into the cavity of another molecule or group of
molecules (known as host). The major structural requirement for inclusion complexation
is a snug fit of the guest into the cavity of host molecule. The cavity of host must be large
enough to accommodate the guest and small enough to eliminate water, so that the total
contact between the water and the nonpolar regions of the host and the guest is reduced.
The most commonly used host molecules are cyclodextrins. Cyclodextrin inclusion is a
molecular phenomenon in which usually only one guest molecule interacts with the
cavity of a cyclodextrin molecule to become entrapped and form a stable association. The
internal surface of cavity is hydrophobic and external is hydrophilic; this is due to the
arrangement of hydroxyl group within the molecule [21].
e. SonocrystallizationRecrystallization of poorly soluble materials using liquid solvents and antisolvents has
also been employed successfully to reduce particle size [22].
The novel approach for particle size reduction based on crystallization by using
ultrasound is Sonocrystallisation. It utilizes ultrasound power characterized by a
frequency range of 20100 kHz for inducing crystallization. It not only enhances the
nucleation rate but also controls size distribution of the active pharmaceutical ingredients
(API) [23].
Most applications use ultrasound in the range 20 kHz-5 MHz [24].
f. Modification of Crystal habits
-
8/22/2019 Assignment I Solubility
18/24
Polymorphism is the ability of an element or compound to crystallize in more then one
crystalline form. Different polymorphs of drugs are chemically identical, but they exhibit
different physicochemical properties including solubility, melting point, density, texture,
stability etc. Broadly polymorphs can be classified as enantiotropes and monotropes
based on thermodynamic properties. In the case of an enantiotropic system, one
polymorphs form can change reversibly into another at a definite transition temperature
below the melting point, while no reversible transition is possible for monotropes. Once
the drug has been characterized fewer than one of this category, further study involves
the detection of metastable form of crystal. Metastable forms are associated with higher
energy and thus higher solubility. Similarly, the amorphous form of drug is always more
suited than crystalline form due to higher energy associated and increase surface area.Generally, the anhydrous form of a drug has greater solubility than the hydrates. This is
because the hydrates are already in interaction with water and therefore have less energy
for crystal breakup in comparison to the anhydrates (i.e. thermodynamically higher
energy state) for further interaction with water. On the other hand, the organic
(nonaqueous) solvates have greater solubility than the nonsolvates.
Some drugs can exist in amorphous form (i.e. having no internal crystal structure). Such
drugs represent the highest energy state and can be considered as super cooled liquids.
They have greater aqueous solubility than the crystalline forms because they require less
energy to transfer a molecule into solvent. Thus, the order for dissolution of different
solid forms of drug is
Amorphous >Metastable polymorph >Stable polymorph
Melting followed by a rapid cooling or recrystallization from different solvents can be
produce metastable forms of a drug [25].
g. Nanotechnology approachesParticle size reduction is the technique followed from past to increase the solubility of the
poorly water soluble drugs, but only converting the drug in micro particle level doesnt
solve the problem as it dont help to increase the saturation point of the respective drug.
But if the same drug is produce in nano crystal form i.e. crystals of size below 2000 nm,
-
8/22/2019 Assignment I Solubility
19/24
it help to improve the rate of absorption, bioavailability after oral administration,
improves in dose proportionality, applicability to administer from any route of
administration, reduction on required dose etc. The nano crystal can be formulated in
nano suspension dosage form and also in tablet and capsule dosage form. The nano
crystals of poorly water soluble drugs are dispersed in dispersion media comprising
water, or non aqueous media, other polymeric media, salts, sugars etc and can be
converted into above mentioned dosage forms [26].
h. Spray dryingSpray drying is a commonly used method of drying a liquid feed through a hot gas.
Typically, this hot gas is air but sensitive materials such as pharmaceuticals and solvents
like ethanol require oxygen-free drying and nitrogen gas is used instead. The liquid feed
varies depending on the material being dried and is not limited to food or pharmaceutical
products and may be a solution, colloid or a suspension. This process of drying is a one
step rapid process and eliminates additional processing [27].
Spray drying of the acid dispersed in acacia solutions resulted in as much as a 50%
improvement in the solubility of poorly water soluble salicylic acid [28].
i. HydrotrophyHydrotrophy designate the increase in solubility in water due to the presence of large
amount of additives. The mechanism by which it improves solubility is more closely
related to complexation involving a weak interaction between the hydrotrophic agents
(sodium benzoate, sodium acetate, sodium alginate, and urea) and the solute. Example:
Solubilisation of Theophylline with sodium acetate and sodium alginate [29].
In addition to the above mentioned approaches some other approaches are made with
certain modification in the existing solubility enhancement techniques, some techniques
are given as follows-
http://en.wikipedia.org/wiki/Medicationhttp://en.wikipedia.org/wiki/Solventhttp://en.wikipedia.org/wiki/Ethanolhttp://en.wikipedia.org/wiki/Oxygenhttp://en.wikipedia.org/wiki/Nitrogenhttp://en.wikipedia.org/wiki/Solutionhttp://en.wikipedia.org/wiki/Colloidhttp://en.wikipedia.org/wiki/Suspension_%28chemistry%29http://en.wikipedia.org/wiki/Suspension_%28chemistry%29http://en.wikipedia.org/wiki/Colloidhttp://en.wikipedia.org/wiki/Solutionhttp://en.wikipedia.org/wiki/Nitrogenhttp://en.wikipedia.org/wiki/Oxygenhttp://en.wikipedia.org/wiki/Ethanolhttp://en.wikipedia.org/wiki/Solventhttp://en.wikipedia.org/wiki/Medication -
8/22/2019 Assignment I Solubility
20/24
i. Use of polyplasdone crospovidoneIn this system the poorly water solubledrugs are formulated with polyplasdone crospovidone while formulating the
drug in tablet dosage form. The polyplasdone crospovidone is super
disintegrant and after reaching to gastricfluid, helps to disintegrates as well
improve the dissolution of poorly soluble drug in gastric fluid [30].
ii. Liquisolid techniquesIn this technique the poorly soluble drug molecule isembedded with non volatile solvent likepolyethylene glycol, propylene
glycol, tween 80, span 20 etc, carrier materials like methyl cellulose, ethyl
cellulose, starch etc, coating materials like silica, aerosols, talc etc, and
disintegrantt like sodium starch glycolaate, cross povidone etc, and formulatedin tablet form, but certain part of liquid remains inside it and while
compression of tablet the care and optimization of process should be made not
to press out the present liquid [31].
iii. Designing of poorly water soluble drugs in controlled release dosage formIn this technique, the poorly water soluble drugs are enclosed, adsorbed or
incorporated in different polymers. After administration of this dosage form, it
make available of the poorly water soluble drug at absorption site for prolong
duration the bioavailability of respective drug get increases [32].
iv. Designing of poorly water soluble drugs in buccal drug delivery systemThebasic philosophy followed in this technique is to avoid the first pass effect and
the possible destruction of active drug by gastric fluids after reaching to
gastrointestinal tract. Thus the poorly water soluble drugs are made available
for absorption from the mucosal layer of buccal cavity [33].
v. Floating granulesIn this technique, poorly water soluble drugs which arehighly absorbed from the mucosal layer of stomach are taken in consideration.
As those drugs which are highly absorbed from wall of stomach are retained
-
8/22/2019 Assignment I Solubility
21/24
in stomach for prolong time the active drug available for absorption will
available for prolong time thus the bioavailability of that drug become good so
that may contribute for the reduction of dose of that drug also. In this method,
the granules of poorly water soluble drugs are so designed that, the drug after
oral administration get disintegrates in gastric fluid giving rises to granules
which get float in gastric fluids available in stomach. This gives rise to the
increase of drug available for absorption for prolong time and reduces the loss
of undissolved drug in fecal matter due to movement of gastrointestinal tract
[33].
11.ConclusionSolubility and permeability of APIs and dissolution characteristics of the dosage forms
have direct effect on pharmacokinetic parameters. This in turn affects the
pharmacological properties of the APIs. There are a number of problems associated with
the new chemical entities bearing the pharmacological values. Among them solubility is
one of the major parameter which directly influence the bioavailability of the drug and
finally the pharmacological response of drug. To overcome this problem especially when
the poorly water-soluble drugs are to be formulated as oral dosage forms, there are
different techniques in practice. Some of them are in practice since long and some are
newly introduced from research activities. The approaches of enhancing the solubility of
poorly soluble drug molecules shows great promise for development of dosage forms
using such APIs.
-
8/22/2019 Assignment I Solubility
22/24
12.References1. Alexander T. Florens, David Atwood. (2006)Physicochemical Principles of
Pharmacy. 4th
ed. Pharmaceutical Press, London.
2. S. J. Carter. (2000) Tutorial Pharmacy.6th ed. CBS Publishers and Distributors, NewDelhi.
3. John H. Block, Edward B. Roche, Taito O. Soine, Charles O. Wlison.InorganicMedicinal and Pharmaceutical Chemistry. Lea and Febiger, Philadelphia.
4. Multisource (generic) pharmaceutical products guidelines on registrationrequirements to establish interchangeability. In: WHO Expert Committee on Specifi
cations for Pharmaceutical Preparations. Fortieth report. Geneva, World Health
Organization (WHO Technical Report Series, No. 937), 2006, Annex 7. 378-379.
5. Proposal to waive in vivo bioequivalence requirements forWHO Model List ofEssential Medicines immediate-release, solid oral dosage forms. In: WHO Expert
Committee on Specifi cations for Pharmaceutical Preparations. Fortieth report.
Geneva, World Health Organization (WHO Technical Report Series, No. 937), 2006,
Annex 8. 391-393.
6. Owen Bentley. Textbook of Pharmaceutics, 8th edition.7. Pardeep K Gupta, Solutions and Phase Equilibria. In Remington: The Science and
Practice of Pharmacy20th ed. Philadelphia College of Pharmacy and Science,
Philadelphia.
8. Adam M. Persky and Jeffrey A. Hughes, Solutions and Solubility.http://www.cop.ufl.edu/safezone/prokai/pha5100/pha5110.htm
9. James K. Solubility and Related Properties, vol. 28, Marcel Dekker Inc., Newyork,986, 127146, 355395.
10.Satish K.P., Kalpesh S.W., Venkatesh B.P., Anup M.A., Dheeraj T.B., Strategies ForSolubility Enhancement Of Poorly Soluble Drugs, I J of Pharmaceutical SciencesReview and Research, 2011, 8 (2), 74-80
11.Solubility of Solutes and Aqueous Solutionshttp://www.chem.lsu.edu/lucid/tutorials/tutorials.html
12.D.Singhal,W. Curatolo, Drug Polymorphism and Dosage Form Design: a practicalperspective, Advanced Drug Delivery Rev., 2004, 56, 335-347.
http://www.cop.ufl.edu/safezone/prokai/pha5100/pha5110.htmhttp://www.chem.lsu.edu/lucid/tutorials/tutorials.htmlhttp://www.chem.lsu.edu/lucid/tutorials/tutorials.htmlhttp://www.cop.ufl.edu/safezone/prokai/pha5100/pha5110.htm -
8/22/2019 Assignment I Solubility
23/24
13.Pinnamaneni S., Das N.G., Das S.K., Formulation Approaches for OrallyAdministered Poorly Soluble Drugs. Pharmazie, 2002, 57, 291300.
14.Ahire B.R., RaneB.R.,Bakliwal S.R., Pawar S.P., Solubility Enhancement of PoorlyWater Soluble Drug by Solid Dispersion Techniques, I J of PharmTech R, 2010, 2
(3), 2007-2015
15.W.L. Chiou, S. Riegelman, Pharmaceutical applications of solid dispersion systems,J. Pharm. Sci. 1971, 60, 1281-1302.
16.Vasu Kumar Kakumanu and Arvind K Bansal, Supercritical Fluid Technology inPharmaceutical Research, Businessbriefing: Labtech, 2004, 71-73.
17.Irene Pasquali, Ruggero Bettini, Ferdinando Giordano, Solid-state chemistry andparticle engineering with supercritical fluids in pharmaceutics, European journal ofpharmaceutical sciences 2006, 27, 299310.
18.Hamsaraj Karanth,1 Vikram Subraya Shenoy and Rayasa Ramachandra Murthy,Industrially Feasible Alternative Approaches in the Manufacture of Solid
Dispersions: A Technical Report, AAPS PharmSciTech 2006; 7 (4) Article 87.
19.M. Perrut, J. Jung, F. Leboeuf, Enhancement of dissolution rate of poorly solubleactive ingredients by supercritical fluid processes Part II: Preparation of composite
particles, International Journal of Pharmaceutics, 2005, 288, 1116.
20.Bhupendra G. Prajapati, Rakesh P. Patel, Ritesh B. Patel, Girish, N. Patel, Hitesh R.Patel and Dr. Madhabhai Patel, Novel Pharmaceutical Methods Improve one of the
Principal Pharmacokinetic Properties of Lipophilic Drug, www.pharmaquality.com
21.R.A. Rajewski, V.J. Stella, Pharmaceutical applications of cyclodextrins. 2. In vivodrug delivery, J. Pharm. Sci., 1996, 85, 1142-1169.
22.Michael Hite, Lead Research Associate, Stephen Turner, Oral Delivery of PoorlySoluble Drugs 400, Pharmaceutical Manufacturing and Packing Sourcer Summer 03
issue. Samedan Ltd. 2003.
23.Sheere Banga, Garima Chawla and Arvind K Bansal, New Trends in theCrystallisation of Active Pharmaceutical Ingredients, Businessbriefing:
Pharmagenerics, 2004, 70-74.
24.Crystallization process using ultrasound, United States Patent 20020031577.
http://www.aapspharmaceutica.com/http://www.pharmaquality.com/http://www.pharmaquality.com/http://www.aapspharmaceutica.com/ -
8/22/2019 Assignment I Solubility
24/24
25.Kawashima Y, Saito M, Takenaka H, Improvement of solubility and dissolution rateof poorly water-soluble salicylic acid by a spray-drying technique. J. Pharm.
Pharmacol. 1975, 27, 1-5. Keck CM, Mller RH, Drug nanocrystals of poorly soluble
drugs produced by high pressure homogenisation. Eur J Pharm Biopharm., 2006, 62,
3-16.
26.Spray drying From Wikipedia, the free encyclopedia. Retrieved fromhttp://en.wikipedia.org
27.Kawashima Y, Saito M, Takenaka H, Improvement of solubility and dissolution rateof poorly water-soluble salicylic acid by a spray-drying technique. J. Pharm.
Pharmacol. 1975, 27, 1-5.
28.Lachman L., Liberman H.A., Kanig J.L.,The Theory and Practice of IndustrialPharmacy, Verghese Publishing, Indian edition, 3rd edn.,1987, 462-466.
29.Polyplasdone crospovidone, The solution for Poorly soluble drug, ispcorp.com30.Spireas S. Liquisolid systems and Methods of Preparing same, US patent 6423339
B1, 2002
31.Spireas S., Bolton M., Liquisolid Systems and Method of Preparing Same, US patent,5968550, 1999
32.Tugba G., Neslihan G., Levent O., Nanocrystal Technology for Oral Delivery ofPoorly Water Soluble Drugs, FABAD J Pharm Sci., 2009, 34, 55-65
33.Anuj K., Sangram K.S., Kumud P., Prithi P.S.K., Ajit S., Naveen P., Review onSolubiltiy Enhancement Techniques For Hydrophobic Drugs, I J of Comprehensive
Pharmacy, 2011, 2(3), 1-7
http://en.wikipedia.org/http://en.wikipedia.org/